KATALOG · NICE TECHNOLOGY APPRAISALS
924 drug appraisals, satu portal.
Telusuri seluruh Technology Appraisal (TA) dan Highly Specialised Technologies (HST) NICE — disaring per disease area, programme, dan keyword. Klik appraisal untuk membuka rekomendasi numbered + extracted methods.
924 hasil
Daftar Appraisal
- TATA1149Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myelomaTABlood and immune system conditions2026-04-30
- TATA1147Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and overTACancermethods ✓2026-04-29
- TATA1148Sodium zirconium cyclosilicate for treating hyperkalaemiaTADiabetes and other endocrinal, nutritional and metabolic conditions2026-04-29
- TATA1146Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitorsTACancermethods ✓2026-04-28
- TATA11452026-04-21
- TATA1144Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)TASkin conditions2026-04-08
- TATA1143Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopauseTAGynaecological conditions2026-03-31
- TATA1142Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophilsTARespiratory conditions2026-03-26
- TATA11402026-03-17
- TATA11412026-03-17
- TATA1139Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatmentTABlood and immune system conditions2026-03-11
- HSTHST35Pegzilarginase for treating arginase-1 deficiency in people 2 years and overHSTDiabetes and other endocrinal, nutritional and metabolic conditions2026-03-04
- TATA11382026-03-02
- TATA1136Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancerTACancermethods ✓2026-02-25
- TATA1137Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TADiabetes and other endocrinal, nutritional and metabolic conditions2026-02-25
- TATA1135Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal)TAInfections2026-02-19
- HSTHST342026-02-18
- TATA1133Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myelomaTABlood and immune system conditions2026-02-18
- TATA1134Dupilumab for treating severe chronic rhinosinusitis with nasal polypsTAEar, nose and throat conditions2026-02-18
- TATA1132Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal)TABlood and immune system conditions2026-02-17
- TATA1129Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTACancermethods ✓2026-02-12
- TATA1131Obinutuzumab with mycophenolate mofetil for treating lupus nephritisTABlood and immune system conditions2026-02-12
- TATA1130Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancerTACancermethods ✓2026-02-11
- TATA11272026-02-04
- TATA1128Targeted-release budesonide for treating primary IgA nephropathyTAKidney conditions2026-02-04
- TATA1126Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapyTANeurological conditions2026-01-28
- TATA1124Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)TABlood and immune system conditions2026-01-27
- TATA1125Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal)TARespiratory conditions2026-01-27
- TATA1123Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)TAEar, nose and throat conditions2026-01-22
- TATA1122Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerTACancer2026-01-21
- TATA1121Acoramidis for treating transthyretin amyloidosis with cardiomyopathyTACardiovascular conditions2026-01-14
- TATA11202026-01-08
- TATA11182026-01-07
- TATA1119Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaTABlood and immune system conditions2026-01-07
- TATA11172025-12-16
- TATA1116Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemiaTABlood and immune system conditions2025-12-11
- TATA1115Vutrisiran for treating transthyretin amyloidosis with cardiomyopathyTACardiovascular conditions2025-12-10
- TATA1113Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphomaTABlood and immune system conditions2025-12-03
- TATA1114Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTABlood and immune system conditions2025-12-03
- TATA11102025-11-19
- TATA1111Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)TARespiratory conditions2025-11-19
- TATA11122025-11-19
- TATA11092025-11-12
- TATA11062025-11-05
- TATA1107Delgocitinib for treating moderate to severe chronic hand eczemaTASkin conditions2025-11-05
- TATA1108Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTACancer2025-11-05
- TATA1102Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)TAKidney conditions2025-10-29
- TATA1104Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TAMusculoskeletal conditions2025-10-22
- TATA1105Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TASkin conditions2025-10-22
- TATA11032025-10-21
- TATA1101Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and overTABlood and immune system conditions2025-10-08
- TATA1099Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTACancer2025-10-01
- TATA11002025-10-01
- TATA1098Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitableTABlood and immune system conditions2025-09-24
- TATA10972025-09-11
- TATA1096Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitisTACardiovascular conditions2025-09-03
- TATA1093Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and overTAEye conditions2025-08-28
- TATA1094Guselkumab for treating moderately to severely active ulcerative colitisTADigestive tract conditions2025-08-28
- TATA1095Guselkumab for previously treated moderately to severely active Crohn's diseaseTADigestive tract conditions2025-08-28
- TATA10922025-08-27
- TATA10912025-08-20
- TATA1090Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinomaTACancer2025-08-19
- TATA10892025-08-13
- TATA10862025-08-06
- TATA1087Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollenTABlood and immune system conditions2025-08-06
- TATA1085Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and overTACystic fibrosis2025-07-30
- TATA10792025-07-23
- TATA1082Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal)TAInfections2025-07-23
- TATA1083Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal)TABlood and immune system conditions2025-07-23
- TATA1084Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)TABlood and immune system conditions2025-07-23
- TATA1080Mirikizumab for previously treated moderately to severely active Crohn's diseaseTADigestive tract conditions2025-07-10
- TATA1081Zanubrutinib for treating relapsed or refractory mantle cell lymphomaTABlood and immune system conditions2025-07-10
- TATA1075Dapagliflozin for treating chronic kidney diseaseTAKidney conditions2025-07-02
- TATA10762025-07-02
- TATA1077Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and overTASkin conditions2025-07-02
- TATA1074Sparsentan for treating primary IgA nephropathyTAKidney conditions2025-06-25
- TATA1078Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal)TADiabetes and other endocrinal, nutritional and metabolic conditions2025-06-25
- TATA1073Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodiesTABlood and immune system conditions2025-06-24
- TATA10712025-06-19
- TATA10722025-06-19
- TATA1070Spesolimab for treating generalised pustular psoriasis flaresTASkin conditions2025-06-18
- TATA1067Linzagolix for treating symptoms of endometriosisTAGynaecological conditions2025-06-04
- TATA10692025-06-04
- TATA1066Somapacitan for treating growth hormone deficiency in people 3 to 17 yearsTADiabetes and other endocrinal, nutritional and metabolic conditions2025-06-03
- TATA10682025-05-29
- TATA10652025-05-28
- TATA10642025-05-22
- TATA10632025-05-15
- TATA10622025-05-12
- TATA10602025-05-08
- TATA1059Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphomaTABlood and immune system conditions2025-05-07
- TATA1061Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)TAMusculoskeletal conditions2025-05-06
- HSTHST332025-04-23
- TATA1058Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)TACancer2025-04-23
- TATA10552025-04-16
- TATA1056Molnupiravir for treating COVID-19TAInfections2025-04-16
- TATA1057Relugolix–estradiol–norethisterone for treating symptoms of endometriosisTAGynaecological conditions2025-04-16
- TATA1053Cladribine for treating active relapsing forms of multiple sclerosisTANeurological conditions2025-04-15
- TATA1054Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and overTABlood and immune system conditions2025-04-15
- HSTHST32Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type BHSTCardiovascular conditions2025-04-02
- TATA1051Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and overTABlood and immune system conditions2025-04-02
- TATA10522025-04-02
- TATA1048Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitableTABlood and immune system conditions2025-03-26
- TATA1049Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemiaTABlood and immune system conditions2025-03-26
- TATA1050Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and overTANeurological conditions2025-03-26
- TATA10462025-03-12
- TATA10472025-03-12
- TATA104512 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mitesTABlood and immune system conditions2025-03-05
- TATA10432025-02-26
- TATA1044Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and overTABlood and immune system conditions2025-02-26
- TATA10412025-02-19
- TATA1042Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTACancer2025-02-19
- TATA1033Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and overTANeurological conditions2025-02-12
- TATA10382025-02-12
- TATA10392025-02-12
- TATA1040Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapyTACancer2025-02-12
- TATA10362025-02-05
- TATA10372025-02-05
- TATA1035Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney diseaseTABlood and immune system conditions2025-01-23
- TATA10322025-01-22
- TATA10342025-01-22
- TATA10312025-01-16
- TATA1028Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)TAInfections2025-01-15
- TATA1029Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal)TABlood and immune system conditions2025-01-15
- TATA10302025-01-15
- TATA10272025-01-09
- TATA1026Tirzepatide for managing overweight and obesityTADiabetes and other endocrinal, nutritional and metabolic conditions2024-12-23
- TATA1025Ublituximab for treating relapsing multiple sclerosisTANeurological conditions2024-12-18
- TATA1023Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTABlood and immune system conditions2024-12-11
- TATA10242024-12-11
- TATA10212024-12-04
- TATA10222024-12-04
- TATA1020Eplontersen for treating hereditary transthyretin-related amyloidosisTADiabetes and other endocrinal, nutritional and metabolic conditions2024-11-27
- TATA10172024-11-20
- TATA1018Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosisTABlood and immune system conditions2024-11-20
- TATA1019Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and overTABlood and immune system conditions2024-11-20
- TATA1016Elafibranor for previously treated primary biliary cholangitisTALiver conditions2024-11-14
- TATA10142024-11-13
- TATA1015Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTABlood and immune system conditions2024-11-13
- TATA1012Avapritinib for treating advanced systemic mastocytosisTABlood and immune system conditions2024-11-06
- TATA1010Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuriaTABlood and immune system conditions2024-10-23
- TATA1013Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemiaTABlood and immune system conditions2024-10-23
- TATA10112024-10-16
- TATA1009Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertensionTAEye conditions2024-10-02
- TATA10082024-09-25
- TATA10072024-09-17
- TATA1006Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TADiabetes and other endocrinal, nutritional and metabolic conditions2024-09-12
- TATA1002Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and overTACardiovascular conditions2024-09-11
- TATA1003Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and overTABlood and immune system conditions2024-09-11
- TATA1004Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusionTAEye conditions2024-09-11
- TATA1005Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangementTACancer2024-09-11
- TATA1000Iptacopan for treating paroxysmal nocturnal haemoglobinuriaTABlood and immune system conditions2024-09-04
- TATA1001Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatmentTABlood and immune system conditions2024-09-04
- TATA999Vibegron for treating symptoms of overactive bladder syndromeTANeurological conditions2024-09-04
- TATA9972024-08-29
- TATA998Risankizumab for treating moderately to severely active ulcerative colitisTADigestive tract conditions2024-08-22
- TATA9952024-08-14
- TATA996Linzagolix for treating moderate to severe symptoms of uterine fibroidsTAGynaecological conditions2024-08-14
- TATA9942024-08-08
- TATA991Abaloparatide for treating osteoporosis after menopauseTADiabetes and other endocrinal, nutritional and metabolic conditions2024-08-07
- TATA993Burosumab for treating X-linked hypophosphataemia in adultsTADiabetes and other endocrinal, nutritional and metabolic conditions2024-08-07
- TATA9922024-07-29
- TATA988Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosisTACystic fibrosis2024-07-24
- TATA989Etranacogene dezaparvovec for treating moderately severe or severe haemophilia BTABlood and immune system conditions2024-07-24
- TATA990Tenecteplase for treating acute ischaemic strokeTACardiovascular conditions2024-07-24
- TATA986Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and overTASkin conditions2024-07-10
- TATA987Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)TABlood and immune system conditions2024-07-10
- TATA984Tafamidis for treating transthyretin amyloidosis with cardiomyopathyTACardiovascular conditions2024-06-19
- TATA982Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TAMusculoskeletal conditions2024-06-13
- TATA9832024-06-12
- TATA979Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutationTABlood and immune system conditions2024-06-05
- TATA9802024-06-05
- TATA9762024-05-29
- TATA9772024-05-29
- TATA978Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)TABlood and immune system conditions2024-05-29
- HSTHST31Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndromeHSTDiabetes and other endocrinal, nutritional and metabolic conditions2024-05-22
- TATA972Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TAEar, nose and throat conditions2024-05-22
- TATA973Atogepant for preventing migraineTANeurological conditions2024-05-15
- TATA974Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTABlood and immune system conditions2024-05-15
- TATA975Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and underTABlood and immune system conditions2024-05-15
- TATA970Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatmentsTABlood and immune system conditions2024-05-08
- TATA9712024-05-08
- TATA967Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and overTABlood and immune system conditions2024-05-01
- TATA969Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)TARespiratory conditions2024-04-30
- TATA968Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TABlood and immune system conditions2024-04-25
- TATA9662024-04-24
- TATA9642024-04-10
- TATA961Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)TACardiovascular conditions2024-03-28
- TATA9622024-03-28
- TATA965Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)TARespiratory conditions2024-03-28
- TATA9582024-03-27
- TATA959Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosisTADiabetes and other endocrinal, nutritional and metabolic conditions2024-03-27
- TATA960Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)TAEye conditions2024-03-27
- TATA957Momelotinib for treating myelofibrosis-related splenomegaly or symptomsTABlood and immune system conditions2024-03-20
- TATA953Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedemaTADiabetes and other endocrinal, nutritional and metabolic conditions2024-03-13
- TATA9552024-03-13
- TATA956Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and overTADigestive tract conditions2024-03-11
- TATA954Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTABlood and immune system conditions2024-03-06
- TATA9522024-02-21
- TATA949Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overTABlood and immune system conditions2024-02-07
Menampilkan 200 teratas dari 924 hasil. Persempit filter untuk melihat sisanya.